Neurology/CNS Phase 1 Deal Benchmarks — Ex-US (2026)
Median upfront of $34M with total deal values reaching $704M in Ex-US territory.
Median Upfront
$34M
Total Deal Value
$469M
Royalty Range
5.1%–10.2%
Territory Multiplier
0.45x
Understanding Neurology/CNS Deal Benchmarks at Phase 1
Phase 1 Neurology/CNS licensing deals in Ex-US territory command a median upfront payment of $34M, with values ranging from $14M at the low end to $55M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the neurology/cns therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Full Benchmark Data
Full Benchmark Table
Low, median, and high ranges for upfront payments, total deal values, and royalty rates.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Comparable Deals
See All Comparable Deals
View 1 comparable Neurology/CNS transactions with upfront payments, total values, and deal structures.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 1 Neurology/CNS deals in Ex-US territory?
More Expert Insights
Territory impact analysis, royalty negotiation strategies, and deal structure guidance.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Related Benchmarks
$15M upfront
Neurology/CNS · Preclinical · Ex-US
$105M upfront
Neurology/CNS · Phase 2 · Ex-US
$232M upfront
Neurology/CNS · Phase 3 · Ex-US
$664M upfront
Neurology/CNS · Approved · Ex-US
$40M upfront
Oncology · Phase 1 · Ex-US
$74M upfront
Immunology · Phase 1 · Ex-US
$103M upfront
Metabolic/Obesity · Phase 1 · Ex-US
$76M upfront
Neurology/CNS · Phase 1 · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open Deal CalculatorCite This Data
Ambrosia Ventures. (2026). Neurology/CNS Phase 1 Deal Benchmarks — Ex-US (2026). Retrieved from https://calculator.ambrosiaventures.co/data/neurology-phase-1-deals-ex-us
<a href="https://calculator.ambrosiaventures.co/data/neurology-phase-1-deals-ex-us">Neurology/CNS Phase 1 Deal Benchmarks — Ex-US (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://calculator.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=neurology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,900+ verified biopharma transactions. Updated monthly.